Answers are grounded in this paper and cite their sources.
Survival rate amongst breast cancer patients has significantly increased over the past 20 years due to improved therapeutic regimens and better screening strategies. Though the mainstay of tumor treatment has been surgical removal of the tumor mass, it is the improvement in adjuvant chemotherapeutic armamentarium that has contributed most to a decline in the death rate. With an increase in knowledge about the biology of breast cancer, treatment regimens have evolved from the use of non-specific drugs that target the bulk of proliferating cells (like paclitaxel and cyclophosphamide), to monoclonal antibodies targeting particular growth factor receptors (such as trastuzumab) and drugs that selectively target specific hormonal pathways (tamoxifen). This review describes the chronological advancement in our understanding of the disease and discusses how that knowledge-base got translated to more effective therapies.
No takes yet. Share an insight, caveat, or question.
Ridham Desai (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: